Volume 2 Issue 1
Pharmacokinetic Exposure and Virologic Response in HIV-1 Infected Pregnant Women Treated with Lopinavir/Ritonavir: Aids Clinical Trials Group Protocol A5153S: A substudy TO A5150
Beverly E. Sha, MD*, Camlin Tierney, PhD, Xin Sun, MS, Alice Stek. M.D., Susan E. Cohn, M.D., M.P.H., Robert W. Coombs, M.D., Ph.D., Barbara Bastow, B.S.N., Francesca T. Aweeka, Pharm.D, and the AIDS Clinical Trials Group (ACTG) 5153s Team
Current Department of Health and Human Services United States guidelines recommend combination antiretroviral therapy for all pregnant women to prevent perinatal transmission of HIV. Lopinavir/ritonavir (LPV/r) twice daily remains a preferred protease inhibitor (PI) for antiretroviral naïve pregnant women. Drug absorption, distribution, metabolism and excretion constitute the basis of drug pharmacokinetics and may all undergo changes during pregnancy. Changes become increasingly pronounced as pregnancy advances and peak during the third trimester.
The Presence of Tuberculosis at the Initiation of Antiretroviral Therapy Predicts Retention in Care: A Retrospective Review of Patients on ART in Nigeria
Joseph Enegela*, Apata Jummai, Epoupa Flora, Onu Eugene, Olutola Ayodotun
Tuberculosis remains an important opportunistic infection among patients that are HIV-positive, and it continues to be a significant cause of mortality in sub-Saharan Africa. Its presence in patients with HIV determines the threshold for commencing antiretroviral therapy, and it is important in predicting long term retention in care. We aimed to determine the outcomes of patients that were co-infected with tuberculosis and HIV at the commencement of antiretroviral therapy.